Newly Emerging Theranostic Agents for Simultaneous Cancertargeted Imaging and Therapy

Area of Science:

• Oncology
• Nanotechnology
• Drug Delivery

Background:

• Personalized oncology increasingly utilizes theranostic agents for integrated tumor diagnosis and therapy.
• Current strategies involve chemical conjugation or nanoplatforms for targeted cancer treatment and detection.

Purpose of the Study:

• To review existing and novel approaches for preparing multifunctional cancer theranostic agents.
• To highlight the potential benefits and limitations of each preparation strategy.
• To provide insights for developing clinically applicable cancer theranostic agents.

Main Methods:

• Review of chemical conjugation methods linking drugs, contrast agents, and targeting ligands.
• Analysis of nanoplatform-based strategies utilizing nanoparticles for targeted delivery and therapy.
• Exploration of emerging approaches using multifunctional small molecules.

Main Results:

• Chemical conjugation offers a direct route for combining therapeutic and diagnostic functionalities.
• Nanoplatforms leverage the enhanced permeability and retention (EPR) effect or ligand conjugation for targeted action.
• Multifunctional small molecules represent a novel and promising strategy for theranostic agent development.

Conclusions:

• Both conjugation and nanoplatform approaches have distinct advantages and challenges for clinical translation.
• Emerging strategies using small molecules show significant potential for creating efficient and specific cancer theranostic agents.
• Further research is needed to optimize these agents for widespread clinical adoption in cancer therapy.